Avantax Advisory Services Inc. Boosts Stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Avantax Advisory Services Inc. raised its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 33.1% during the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 1,624 shares of the biopharmaceutical company's stock after acquiring an additional 404 shares during the period. Avantax Advisory Services Inc.'s holdings in Regeneron Pharmaceuticals were worth $1,157,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds have also bought and sold shares of REGN. Empowered Funds LLC increased its position in Regeneron Pharmaceuticals by 7.1% during the third quarter. Empowered Funds LLC now owns 1,652 shares of the biopharmaceutical company's stock valued at $1,737,000 after acquiring an additional 109 shares during the last quarter. Thrivent Financial for Lutherans increased its position in Regeneron Pharmaceuticals by 16.7% during the third quarter. Thrivent Financial for Lutherans now owns 9,120 shares of the biopharmaceutical company's stock valued at $9,587,000 after acquiring an additional 1,306 shares during the last quarter. AMG National Trust Bank increased its position in Regeneron Pharmaceuticals by 14.6% during the third quarter. AMG National Trust Bank now owns 220 shares of the biopharmaceutical company's stock valued at $231,000 after acquiring an additional 28 shares during the last quarter. LMR Partners LLP bought a new position in Regeneron Pharmaceuticals during the third quarter valued at $241,000. Finally, Pathstone Holdings LLC grew its holdings in shares of Regeneron Pharmaceuticals by 0.4% in the third quarter. Pathstone Holdings LLC now owns 14,931 shares of the biopharmaceutical company's stock worth $15,696,000 after purchasing an additional 65 shares during the last quarter. Institutional investors own 83.31% of the company's stock.

Remove Ads

Analyst Ratings Changes

REGN has been the topic of a number of research analyst reports. Canaccord Genuity Group cut shares of Regeneron Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a report on Tuesday, December 17th. Truist Financial cut their price target on shares of Regeneron Pharmaceuticals from $1,126.00 to $1,004.00 and set a "buy" rating on the stock in a report on Wednesday, January 8th. UBS Group cut shares of Regeneron Pharmaceuticals from a "buy" rating to a "neutral" rating and cut their price target for the stock from $1,130.00 to $738.00 in a report on Thursday, January 16th. Leerink Partners upgraded shares of Regeneron Pharmaceuticals from a "market perform" rating to an "outperform" rating and upped their price target for the stock from $762.00 to $834.00 in a report on Wednesday, February 5th. Finally, Robert W. Baird cut their price target on shares of Regeneron Pharmaceuticals from $940.00 to $759.00 and set a "neutral" rating on the stock in a report on Wednesday, February 5th. One research analyst has rated the stock with a sell rating, six have issued a hold rating, seventeen have issued a buy rating and two have issued a strong buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $973.13.

Regeneron Pharmaceuticals Stock Down 0.6 %

NASDAQ:REGN traded down $4.14 during mid-day trading on Friday, hitting $658.48. 1,869,108 shares of the company's stock traded hands, compared to its average volume of 634,475. The company has a debt-to-equity ratio of 0.09, a quick ratio of 3.95 and a current ratio of 4.73. The company has a market capitalization of $71.99 billion, a P/E ratio of 17.20, a P/E/G ratio of 2.34 and a beta of 0.27. The company has a fifty day moving average of $689.43 and a 200 day moving average of $815.71. Regeneron Pharmaceuticals, Inc. has a twelve month low of $642.00 and a twelve month high of $1,211.20.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last posted its quarterly earnings data on Tuesday, February 4th. The biopharmaceutical company reported $12.07 earnings per share (EPS) for the quarter, beating the consensus estimate of $11.21 by $0.86. The firm had revenue of $3.79 billion for the quarter, compared to the consensus estimate of $3.76 billion. Regeneron Pharmaceuticals had a net margin of 31.07% and a return on equity of 16.32%. The company's revenue for the quarter was up 10.3% compared to the same quarter last year. During the same quarter in the prior year, the company posted $11.86 earnings per share. On average, analysts forecast that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current year.

Regeneron Pharmaceuticals Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Thursday, March 20th. Shareholders of record on Thursday, February 20th were issued a $0.88 dividend. The ex-dividend date was Thursday, February 20th. This represents a $3.52 dividend on an annualized basis and a dividend yield of 0.53%. Regeneron Pharmaceuticals's dividend payout ratio is currently 2.30%.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.